Publications by authors named "Irina Davidenko"

Claim this Profile
R
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran

Lancet Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
Rebecca Kristeleit, Irina Davidenko, Vadim Shirinkin, Fatima El-Khouly, Igor Bondarenko

Gynecol Oncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Amit M Oza, Frédéric Selle, Irina Davidenko, Jacob Korach, Cesar Mendiola

Int J Gynecol Cancer· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.
Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, Anna Swieboda-Sadlej, Niall C Tebbutt, Irina Davidenko

Clin Cancer Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Timothy Iveson, Ross C Donehower, Irina Davidenko, Sergey Tjulandin, Andrzej Deptala

Lancet Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Elizabeth Poplin, Harpreet Wasan, Lindsey Rolfe, Mitch Raponi, Tone Ikdahl, Irina Davidenko

J Clin Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Jan B Vermorken, Jan Stöhlmacher-Williams, Irina Davidenko, Lisa Licitra, Eric Winquist

Lancet Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Josep Tabernero, Rocio Garcia-Carbonero, James Cassidy, Alberto Sobrero, Eric Van Cutsem, Irina Davidenko

Clin Cancer Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversible holographic recording media based on polymeric composites and their use in energy-saving technologies.
Nikolay Davidenko, Irina Davidenko, Alexandr Ishchenko, Andrey Kulinich, Valeriy Pavlov

Appl Opt· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Ghassan K Abou-Alfa, Philip Johnson, Jennifer J Knox, Marinela Capanu, Irina Davidenko

JAMA· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
Douglas E Peterson, Nicholas P Barker, Lilia I Akhmadullina, Irina Rodionova, Nailya Z Sherman, Irina S Davidenko

J Clin Oncol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis